A case series on the use of lavendula oil capsules in patients suffering from major depressive disorder and symptoms of psychomotor agitation, insomnia and anxiety.
Desain Studi
- Jenis Studi
- Case Reports
- Ukuran Sampel
- 8
- Populasi
- Patients with major depressive disorder (MDD) and symptoms of anxiety, insomnia, and psychomotor agitation at Charité-Universitätsmedizin Berlin
- Intervensi
- A case series on the use of lavendula oil capsules in patients suffering from major depressive disorder and symptoms of psychomotor agitation, insomnia and anxiety. Lasea (lavender oil capsules) 80 mg; dosage details not specified
- Pembanding
- antidepressant medications (adjunct use)
- Luaran Utama
- Change in Hamilton Rating Scale for Depression (HAMD-17) total score and subscores
- Arah Efek
- Positive
- Risiko Bias
- High
Abstrak
OBJECTIVE: Symptoms of agitation, anxiety and insomnia are frequent among patients with major depressive disorder (MDD) during the first weeks of psychiatric care. But a substantial number of patients declines taking pharmaceutical medication to avoid side effects. Therefore, an alternative herbal medication is needed. Clinical studies demonstrated that lavender oil capsules, termed Lasea®, have an anxiolytic effect comparable to Lorazepam and significantly reduce insomnia and agitation in non-depressed patients. Therefore, the aim of this retrospective case series was to analyze the effectiveness of Lasea® for patients with MDD and symptoms of anxiety, insomnia and psychomotor agitation. DESIGN: Eight cases were analyzed retrospectively regarding the dosage, length of treatment, possible side effects and effectiveness of Lasea®. SETTING: All cases were treated at the Department of Psychiatry at Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin in a naturalistic setting. MAIN OUTCOME MEASURE: Effectiveness was measured by a change in the Hamilton Rating Scale for Depression (HAMD-17) total score and subscores. RESULTS: In 6 cases, the combination of Lasea® and an antidepressant resulted in a reduction of MDD. Lasea® also reduced agitation in 6 cases. Psychological anxiety was reduced in 5, somatic anxiety in 4 cases whereas sleep-onset and sleep-maintenance insomnia improved in 3 cases each. CONCLUSIONS: The results demonstrate that Lasea® reduces some of the anxiety related symptoms and sleep disturbances in MDD patients. Furthermore Lasea® significantly reduces psychomotor agitation. Additionally, the results indicate a significant global improvement stemming from the combinational therapy of Lasea® and antidepressant medication.
TL;DR
The results demonstrate that Lasea® reduces some of the anxiety related symptoms and sleep disturbances in MDD patients and indicates a significant global improvement stemming from the combinational therapy of LaseA® and antidepressant medication.